MELBOURNE, Australia, June 27,
2022 /PRNewswire/ -- Incannex Healthcare
Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the
'Company') a clinical-stage pharmaceutical company developing
unique medicinal cannabinoid pharmaceutical products and
psychedelic medicine therapies for unmet medical needs, today
announced that Dr. Paul Liknaitzky,
Head of Clinical Psychedelic Research at Monash University and
Chief Principal Investigator for Incannex's psilocybin-assisted
psychotherapy, will present an overview of progress achieved in
Incannex's psychedelic medicine program at the H.C. Wainwright
First Annual Mental Health Conference, taking place June 27, 2022. Joel
Latham, Managing Director and Chief Executive Officer of
Incannex, will host virtual meetings with institutional investors
during the conference.
The on-demand presentation will be available for viewing
beginning at 7:00 a.m. U.S. EDT on
June 27, 2022. A webcast of the
presentation will be available on Incannex's website at:
https://www.incannex.com.au/investors/ and will be archived for a
period of 90 days following the event.
This announcement has been approved for release to ASX by the
Incannex board of directors.
About Incannex Healthcare
Limited
Incannex is a clinical stage pharmaceutical development company
that is developing unique medicinal cannabis pharmaceutical
products and psychedelic medicine therapies for the treatment of
anxiety disorders, obstructive sleep apnoea (OSA), traumatic brain
injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma,
bronchitis), rheumatoid arthritis and inflammatory bowel disease.
U.S. FDA approval and registration, subject to ongoing clinical
success, is being pursued for each drug and therapy under
development. Each indication represents major global markets and
currently have no, or limited, existing registered pharmacotherapy
(drug) treatments available to the public.
Incannex has a strong patent filing strategy in place as it
develops its products and therapies in conjunction with its medical
and scientific advisory board and partners. Incannex is listed on
the Australian Stock Exchange (ASX) with stock code "IHL" and also
has American Depository Shares listed on NASDAQ under code
"IXHL".
Website: www.incannex.com.au
Investors:
investors@incannex.com.au
Forward-looking
statements
This press release contains "forward-looking statements" within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made as of the date they were first issued and were
based on current expectations and estimates, as well as the beliefs
and assumptions of management. The forward-looking statements
included in this press release represent Incannex's views as of the
date of this press release. Incannex anticipates that subsequent
events and developments may cause its views to change. Incannex
undertakes no intention or obligation to update or revise any
forward-looking statements, whether as of a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing Incannex's
views as of any date after the date of this press release.
Contact Information
Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au
US IR Contact
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/incannex-to-present-at-the-hc-wainwright-first-annual-mental-health-conference-301575448.html
SOURCE Incannex Healthcare Limited